117 related articles for article (PubMed ID: 23629686)
1. Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.
Szczurek E; Misra N; Vingron M
Int J Cancer; 2013 Nov; 133(9):2123-32. PubMed ID: 23629686
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
3. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Shen Y; Li J; Nitta M; Futalan D; Steed T; Treiber JM; Taich Z; Stevens D; Wykosky J; Chen HZ; Carter BS; Becher OJ; Kennedy R; Esashi F; Sarkaria JN; Furnari FB; Cavenee WK; Desai A; Chen CC
Oncotarget; 2015 May; 6(14):11751-67. PubMed ID: 26059434
[TBL] [Abstract][Full Text] [Related]
4. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
5. Cancer: mixing cocktails.
Sawyers CL
Nature; 2007 Oct; 449(7165):993-6. PubMed ID: 17960228
[No Abstract] [Full Text] [Related]
6. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
Kim HJ; Cho JH; Kim JR
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
9. IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals.
Ping Y; Zhang H; Deng Y; Wang L; Zhao H; Pang L; Fan H; Xu C; Li F; Zhang Y; Gong Y; Xiao Y; Li X
Mol Biosyst; 2014 Aug; 10(8):2031-42. PubMed ID: 24911613
[TBL] [Abstract][Full Text] [Related]
10. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer.
Li J; Su W; Zhang S; Hu Y; Liu J; Zhang X; Bai J; Yuan W; Hu L; Cheng T; Zetterberg A; Lei Z; Zhang J
Cancer Sci; 2015 May; 106(5):642-9. PubMed ID: 25702787
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme.
Liu KJ; Chen CT; Hu WS; Hung YM; Hsu CY; Chuang BF; Juang SH
Int J Oncol; 2004 Mar; 24(3):581-90. PubMed ID: 14767543
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to
Lee E; Pain M; Wang H; Herman JA; Toledo CM; DeLuca JG; Yong RL; Paddison P; Zhu J
Cancer Res; 2017 Oct; 77(20):5518-5529. PubMed ID: 28855212
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
[TBL] [Abstract][Full Text] [Related]
16. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
19. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
Ye H; Zhang X; Chen Y; Liu Q; Wei J
Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
[TBL] [Abstract][Full Text] [Related]
20. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
Michiue H; Eguchi A; Scadeng M; Dowdy SF
Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
